Delta-9-tetrahydrocannabinol (THC) in the treatment of end-stage open-angle glaucoma

Allan J. Flach, Douglas R. Anderson, George L. Spaeth, Louis Cantor

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Purpose: Evidence exists that the administration of cannabinoid derivatives can lower intraocular pressure. Some patients with glaucoma believe they are being deprived of a potentially beneficial treatment. Therefore, the Research Advisory Panel of California instituted the Cannabis Therapeutic Research Program to permit compassionate access to cannabinoid derivatives. Data about the potential therapeutic usefulness and toxicity of these agents were collected. This study reviews the results of this program with the specific aim of providing further direction for these investigational efforts. Methods: A survey of local ophthalmologists indicated an impressive interest in participating in and contributing patients with glaucoma unresponsive to treatment to this study. Appropriate patients were treated with either orally administered delta-9-tetrahydrocannabinol capsules or inhaled marijuana in addition to their existing therapeutic regimen. Results: Although 20 ophthalmologists were approved as investigators, only nine patients were enrolled in the study. An initial decrease in intraocular pressure was observed in all patients, and the investigator's therapeutic goal was met in four of the nine patients. However, the decreases in intraocular pressure were not sustained, and all patients elected to discontinue treatment within 1 to 9 months for various reasons. Conclusions: This uncontrolled, unmasked, nonrandomized study does not permit definitive conclusions about the efficacy or toxicity of cannabinoids in the treatment of glaucoma. There is an impression that this treatment can lower intraocular pressure, but the development of tolerance and significant systemic toxicity appears to limit the usefulness of this potential treatment. Both patients and ophthalmologists greatly appreciated the opportunity to participate in this study.

Original languageEnglish (US)
Pages (from-to)215-224
Number of pages10
JournalTransactions of the American Ophthalmological Society
Volume100
StatePublished - 2002
Externally publishedYes

Fingerprint

Dronabinol
Open Angle Glaucoma
Intraocular Pressure
Cannabinoids
Glaucoma
Therapeutics
Cannabis
Research Personnel
Therapeutic Human Experimentation
Capsules

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Delta-9-tetrahydrocannabinol (THC) in the treatment of end-stage open-angle glaucoma. / Flach, Allan J.; Anderson, Douglas R.; Spaeth, George L.; Cantor, Louis.

In: Transactions of the American Ophthalmological Society, Vol. 100, 2002, p. 215-224.

Research output: Contribution to journalArticle

@article{a9594600958f4e86af75494bdf4d4ce7,
title = "Delta-9-tetrahydrocannabinol (THC) in the treatment of end-stage open-angle glaucoma",
abstract = "Purpose: Evidence exists that the administration of cannabinoid derivatives can lower intraocular pressure. Some patients with glaucoma believe they are being deprived of a potentially beneficial treatment. Therefore, the Research Advisory Panel of California instituted the Cannabis Therapeutic Research Program to permit compassionate access to cannabinoid derivatives. Data about the potential therapeutic usefulness and toxicity of these agents were collected. This study reviews the results of this program with the specific aim of providing further direction for these investigational efforts. Methods: A survey of local ophthalmologists indicated an impressive interest in participating in and contributing patients with glaucoma unresponsive to treatment to this study. Appropriate patients were treated with either orally administered delta-9-tetrahydrocannabinol capsules or inhaled marijuana in addition to their existing therapeutic regimen. Results: Although 20 ophthalmologists were approved as investigators, only nine patients were enrolled in the study. An initial decrease in intraocular pressure was observed in all patients, and the investigator's therapeutic goal was met in four of the nine patients. However, the decreases in intraocular pressure were not sustained, and all patients elected to discontinue treatment within 1 to 9 months for various reasons. Conclusions: This uncontrolled, unmasked, nonrandomized study does not permit definitive conclusions about the efficacy or toxicity of cannabinoids in the treatment of glaucoma. There is an impression that this treatment can lower intraocular pressure, but the development of tolerance and significant systemic toxicity appears to limit the usefulness of this potential treatment. Both patients and ophthalmologists greatly appreciated the opportunity to participate in this study.",
author = "Flach, {Allan J.} and Anderson, {Douglas R.} and Spaeth, {George L.} and Louis Cantor",
year = "2002",
language = "English (US)",
volume = "100",
pages = "215--224",
journal = "Transactions of the American Ophthalmological Society",
issn = "0065-9533",
publisher = "American Ophthalmological Society",

}

TY - JOUR

T1 - Delta-9-tetrahydrocannabinol (THC) in the treatment of end-stage open-angle glaucoma

AU - Flach, Allan J.

AU - Anderson, Douglas R.

AU - Spaeth, George L.

AU - Cantor, Louis

PY - 2002

Y1 - 2002

N2 - Purpose: Evidence exists that the administration of cannabinoid derivatives can lower intraocular pressure. Some patients with glaucoma believe they are being deprived of a potentially beneficial treatment. Therefore, the Research Advisory Panel of California instituted the Cannabis Therapeutic Research Program to permit compassionate access to cannabinoid derivatives. Data about the potential therapeutic usefulness and toxicity of these agents were collected. This study reviews the results of this program with the specific aim of providing further direction for these investigational efforts. Methods: A survey of local ophthalmologists indicated an impressive interest in participating in and contributing patients with glaucoma unresponsive to treatment to this study. Appropriate patients were treated with either orally administered delta-9-tetrahydrocannabinol capsules or inhaled marijuana in addition to their existing therapeutic regimen. Results: Although 20 ophthalmologists were approved as investigators, only nine patients were enrolled in the study. An initial decrease in intraocular pressure was observed in all patients, and the investigator's therapeutic goal was met in four of the nine patients. However, the decreases in intraocular pressure were not sustained, and all patients elected to discontinue treatment within 1 to 9 months for various reasons. Conclusions: This uncontrolled, unmasked, nonrandomized study does not permit definitive conclusions about the efficacy or toxicity of cannabinoids in the treatment of glaucoma. There is an impression that this treatment can lower intraocular pressure, but the development of tolerance and significant systemic toxicity appears to limit the usefulness of this potential treatment. Both patients and ophthalmologists greatly appreciated the opportunity to participate in this study.

AB - Purpose: Evidence exists that the administration of cannabinoid derivatives can lower intraocular pressure. Some patients with glaucoma believe they are being deprived of a potentially beneficial treatment. Therefore, the Research Advisory Panel of California instituted the Cannabis Therapeutic Research Program to permit compassionate access to cannabinoid derivatives. Data about the potential therapeutic usefulness and toxicity of these agents were collected. This study reviews the results of this program with the specific aim of providing further direction for these investigational efforts. Methods: A survey of local ophthalmologists indicated an impressive interest in participating in and contributing patients with glaucoma unresponsive to treatment to this study. Appropriate patients were treated with either orally administered delta-9-tetrahydrocannabinol capsules or inhaled marijuana in addition to their existing therapeutic regimen. Results: Although 20 ophthalmologists were approved as investigators, only nine patients were enrolled in the study. An initial decrease in intraocular pressure was observed in all patients, and the investigator's therapeutic goal was met in four of the nine patients. However, the decreases in intraocular pressure were not sustained, and all patients elected to discontinue treatment within 1 to 9 months for various reasons. Conclusions: This uncontrolled, unmasked, nonrandomized study does not permit definitive conclusions about the efficacy or toxicity of cannabinoids in the treatment of glaucoma. There is an impression that this treatment can lower intraocular pressure, but the development of tolerance and significant systemic toxicity appears to limit the usefulness of this potential treatment. Both patients and ophthalmologists greatly appreciated the opportunity to participate in this study.

UR - http://www.scopus.com/inward/record.url?scp=0036988167&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036988167&partnerID=8YFLogxK

M3 - Article

C2 - 12545695

AN - SCOPUS:0036988167

VL - 100

SP - 215

EP - 224

JO - Transactions of the American Ophthalmological Society

JF - Transactions of the American Ophthalmological Society

SN - 0065-9533

ER -